Ann Dermatol.  2016 Feb;28(1):121-122. 10.5021/ad.2016.28.1.121.

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases

• Kim YS
• Kim HJ
• Lee S
• Park YL

• KMID: 2429497
• DOI: http://doi.org/10.5021/ad.2016.28.1.121

Abstract

No abstract available.

MeSH Terms

Psoriasis*
Ustekinumab

Figure

• 

  Fig. 1 A 42-year-old man presented with whole body erythema with scanty scales. He responded well to ustekinumab (A: baseline, B: 28 weeks after the treatment, C: 76 weeks after the treatment).

• 

  Fig. 2 A 26-year-old man. (A) Baseline: normal skin islands are noticeable within the diffuse erythroderma. Clinical improvement was significant and sustained (B) 28 weeks after the treatment and (C) 112 weeks after the treatment, respectively.

Reference

1. Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010; 62:655–662.

2. Agusti-Mejias A, Messeguer F, García R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013; 25:368–370.

3. Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013; 5:254–259.

4. Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011; 38:1096–1099.

5. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010; 162:1144–1146.